%0 Journal Article
%T 寿胎丸加减联合低分子肝素干预早期复发性流产血栓前状态的临床研究
Clinical study of Shoutaiwan Modified and Low Molecular Weight Heparin on the Prethrombotic State of Early Recurrent Mis-carriage
%A 郭蕊
%A 苏丹
%A 张娜娜
%J Medical Diagnosis
%P 132-136
%@ 2164-5418
%D 2021
%I Hans Publishing
%R 10.12677/MD.2021.113021
%X 目的：观察寿胎丸加减联合低分子肝素治疗血栓前状态所致复发性流产的临床疗效。方法：将60例血栓前状态所致复发性流产的患者作为研究对象，随机分为治疗组和对照组各30例。治疗组予寿胎丸加减联合低分子肝素治疗，对照组予低分子肝素治疗。观察比较患者治疗前后FIB (纤维蛋白原)、D-Dimer (D-二聚体)凝血功能指标、子宫动脉血流动力学变化与孕12周的胚胎存活率。结果：治疗前后组内比较，两组FIB、D-Dimer水平差异有统计学意义(P < 0.05)；组间治疗后比较，FIB、D-Dimer水平差异有统计学意义，治疗组明显低于对照组(P < 0.05)。子宫动脉血流阻力参数S/D、PI、RI降低，治疗组上述指标改善较对照组明显(P < 0.05或 < 0.01)。治疗组孕12周胚胎存活率为93.34%，高于对照组的76.66%，组间孕12周胚胎存活率比较，差异有统计学意义，治疗组明显高于对照组(P < 0.05)。结论：血栓前状态的早期复发性流产患者使用寿胎丸加减联合低分子肝素治疗疗效满意，可有效改善患者的血栓前状态，提高保胎成功率。
Objective: To observe the clinical efficacy of Shoutaiwan plus or minus combined with low molecular weight heparin in the treatment of recurrent miscarriage caused by a prethrombotic state. Methods: Sixty patients with recurrent miscarriage caused by prethrombotic state were taken as the re-search objects, and they were randomly divided into treatment group and control group with 30 cases each. The treatment group was treated with Shoutaiwan plus or minus low molecular weight heparin, and the control group was treated with low molecular heparin. Observe and compare the FIB (fibrinogen), D-Dimer (D-dimer) coagulation function indexes, uterine artery hemodynamic changes before and after treatment, and the embryo survival rate at 12 weeks of pregnancy. Results: Before and after treatment, the difference in FIB and D-Dimer levels between the two groups was statistically significant (P < 0.05); after treatment, the differences in FIB and D-Dimer levels were statistically significant, and the treatment group was significantly lower than that Control group (P < 0.05). Uterine artery blood flow resistance parameters S/D, PI, and RI decreased, and the above indicators in the treatment group improved significantly compared with the control group (P < 0.05 or < 0.01). The embryo survival rate at 12 weeks in the treatment group was 93.34%, which was higher than 76.66% in the control group. There was a statistically significant difference in the embryo survival rate at 12 weeks in the treatment group. The treatment group was significantly higher than the control group (P < 0.05). Conclusion: Patients with prethrombotic state and early recurrent miscarriage using Shoutaiwan plus or minus combined low-molecular-weight heparin have a satisfactory therapeutic effect, which can effectively improve the patient’s prethrombotic state and increase the success rate of pregnancy loss.
%K 寿胎丸，低分子肝素，血栓前状态，早期复发性流产
Shoutaiwan
%K Low Molecular Weight Heparin
%K Prethrombotic State
%K Early Recurrent Miscarriage
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=45324